Feb 14 (Reuters) - SanBio Co Ltd
* Says co and Teijin Limited would terminate the exclusive licensing agreement signed in 2009, regarding the development and marketing of SB623 for stroke treatment in Japan
Source text in Japanese: goo.gl/1xt25t
Further company coverage: (Beijing Headline News)